לונג

TCON 15Min Scalpers edition

מעודכן
test
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
הערה
$1.93 BUY
הערה
Reaffirmation into $31 target
Beyond Technical AnalysisTCONTrend AnalysisWave Analysis

כתב ויתור